Compare GABC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | NUVB |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1995 | 2020 |
| Metric | GABC | NUVB |
|---|---|---|
| Price | $49.77 | $5.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $47.67 | $11.38 |
| AVG Volume (30 Days) | 94.6K | ★ 4.6M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | 8.13 | ★ 71.56 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $487,401,000.00 | $62,902,000.00 |
| Revenue This Year | $16.78 | $203.82 |
| Revenue Next Year | $3.98 | $58.18 |
| P/E Ratio | $26.18 | ★ N/A |
| Revenue Growth | 37.80 | ★ 698.96 |
| 52 Week Low | $37.19 | $3.00 |
| 52 Week High | $52.23 | $9.75 |
| Indicator | GABC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 37.92 |
| Support Level | $48.85 | $5.28 |
| Resistance Level | $51.97 | $6.25 |
| Average True Range (ATR) | 0.80 | 0.29 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 69.15 | 12.06 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.